✦ LIBER ✦

Comparison of the pharmacodynamic effect of muzolimine and furosemide in patients with advanced chronic renal insufficiency

✍ Scribed by P. Schmidt; D. Loew; J. Dýcka; H. Kopsa; P. Balcke; J. Zazgornik; E. Deutsch

Publisher: Springer
Year: 1978
Tongue: English
Weight: 398 KB
Volume: 14
Category: Article
ISSN: 0031-6970
DOI: 10.1007/bf00716380

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Comparison of the effects of muzolimine

Comparison of the effects of muzolimine and furosemide in patients with end-stage renal failure on chronic dialysis

✍ P. Schmidt; D. Loew; J. Dycka; H. Kopsa; P. Balcke; J. Zazgornik; E. Deutsch 📂 Article 📅 1981 🏛 Springer 🌐 English ⚖ 388 KB

Pharmacokinetics and pharmacodynamics of

Pharmacokinetics and pharmacodynamics of torasemide in patients with chronic renal insufficiency—Preliminary evaluation

✍ D. Craig Brater; David R. Rudy; James R. Voelker; Paula K. Greene; Todd Gehr; Do 📂 Article 📅 1993 🏛 Springer US 🌐 English ⚖ 433 KB

Comparison of the short-term effects of

Comparison of the short-term effects of the loop diuretic piretanide and furosemide in patients with renal insufficiency

✍ C. Marone; F. C. Reubi; W. Lahn 📂 Article 📅 1984 🏛 Springer 🌐 English ⚖ 440 KB

Comparison of the pharmacodynamic effect

Comparison of the pharmacodynamic effects of furosemide and BAY g 2821 and correlation of the pharmacodynamics and pharmacokinetics of BAY g 2821 (muzolimine)

✍ D. Loew; W. Ritter; J. Dýcka 📂 Article 📅 1977 🏛 Springer 🌐 English ⚖ 378 KB

Acute effects of acetylsalicylic acid in

Acute effects of acetylsalicylic acid in patients with chronic renal insufficiency

✍ K. J. Berg 📂 Article 📅 1977 🏛 Springer 🌐 English ⚖ 604 KB

Oral pharmacokinetics of pirenzepine in

Oral pharmacokinetics of pirenzepine in patients with chronic renal insufficiency, failure, and maintenance haemodialysis

✍ T. MacGregor; K. Matzek; J. Keirns; M. Vinocur; A. Chonko 📂 Article 📅 1990 🏛 Springer 🌐 English ⚖ 215 KB

The pharmacokinetic properties of pirenzepine following administration of a single, 50 mg oral dose were evaluated in three groups of subjects: group I, end stage renal disease requiring maintenance haemodialysis (CLCR 0 to 10 ml.min-1); group II, moderate renal insufficiency (CLCR 10 to 30 ml.min-1